<p>CreativeOne Wealth LLC 在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Lantheus Holdings, Inc.（NASDAQ:LNTH - 免费报告）中的股份增加了 26.8%。该机构投资者在本季度额外购买了 4,316 股后，持有 20,396 股该医疗设备提供商的股票。CreativeOne Wealth LLC 在 Lantheus 的持股在最近的报告期末价值为 1,670,000 美元。</p>
<ul>
<li>制药火售：3 只 RSI 显示你不应忽视的股票</li>
</ul>
<p>其他大型投资者最近也对该公司的持仓进行了调整。Nuveen LLC 在第一季度购买了价值约 55,941,000 美元的 Lantheus 新股份。Epoch Investment Partners Inc.在第一季度购买了价值约 35,548,000 美元的 Lantheus 新股份。Mackenzie Financial Corp 在第一季度将其在 Lantheus 的持股增加了 129.2%。Mackenzie Financial Corp 现在拥有 497,437 股该医疗设备提供商的股票，价值为 48,550,000 美元，此前在上个季度又购买了 280,381 股。Nitorum Capital L.P.在第一季度购买了价值约 23,261,000 美元的 Lantheus 新股份。最后，Reinhart Partners LLC 在第二季度将其在 Lantheus 的持仓增加了 16.4%。Reinhart Partners LLC 现在拥有 1,403,659 股该医疗设备提供商的股票，价值为 114,905,000 美元，此前在上个季度又购买了 197,719 股。99.06% 的股票由机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>一些股票研究分析师最近对 LNTH 股票发表了评论。B. Riley 在 2023 年 9 月 16 日的研究报告中将 Lantheus 的目标价格从 109.00 美元下调至 84.00 美元，并对该公司给予了 “买入” 评级。Truist Financial 在 2023 年 11 月 10 日的报告中重申了 “持有” 评级，并将 Lantheus 的目标价格设定为 61.00 美元（之前为 63.00 美元）。Mizuho 在 2023 年 8 月 7 日的研究报告中将 Lantheus 的目标价格从 120.00 美元下调至 70.00 美元，并对该股票给予了 “跑赢大盘” 评级。JMP Securities 在 2023 年 8 月 7 日的研究报告中将 Lantheus 的目标价格从 112.00 美元下调至 73.00 美元，并对该股票给予了 “市场跑赢” 评级。最后，Weiss Ratings 在 2023 年 10 月 25 日的研究报告中将 Lantheus 的评级从 “持有（c-）” 下调至 “卖出（d+）”。四位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，共识目标价格为 74.17 美元。</p>
<ul>
<li>大规模突破：该 ETF 信号显示小型股将大幅上涨</li>
</ul>
<p><strong>查看我们关于 LNTH 的最新报告</strong></p>
<h2>Lantheus 股价下跌 0.5%</h2>
<p>Lantheus 股票在周四开盘价为 58.75 美元。该股票的 50 日移动平均价格为 54.28 美元，200 日移动平均价格为 64.44 美元。该公司的市值为 39 亿美元，市盈率为 15.63，贝塔值为 0.04。Lantheus Holdings, Inc.的 52 周低点为 47.25 美元，52 周高点为 111.29 美元。该公司的速动比率为 4.07，流动比率为 4.29，债务股本比率为 0.49。</p>
<ul>
<li>这些医疗设备制造商准备反弹吗？</li>
</ul>
<p>Lantheus（NASDAQ:LNTH - 获取免费报告）最后一次公布季度财报是在 2023 年 5 月 17 日。该医疗设备提供商报告本季度每股收益为 0.05 美元。Lantheus 的净利润率为 17.82%，股本回报率为 34.06%。该业务在本季度的收入为 9251 万美元。卖方分析师预计 Lantheus Holdings, Inc.在本年度将发布 6.01 美元的每股收益。</p>
<h2>Lantheus 简介</h2>
<p>（免费报告）</p>
<p>Lantheus Holdings, Inc.开发、制造和商业化诊断和治疗产品，帮助临床医生在全球范围内诊断和治疗心脏病、癌症及其他疾病。它提供 DEFINITY，一种用于超声心动图检查的可注射超声增强剂；TechneLite，一种用于核医学程序的锝生成器；氙-133，一种用于评估肺功能的放射性药物气体；Neurolite，一种可注射成像剂，用于识别因中风导致的脑部血流被阻断或减少的区域；Cardiolite，一种可注射的 Tc-99m 标记成像剂，用于评估心肌的血流；以及 PYLARIFY，一种 F 18 标记的 PSMA 靶向 PET 成像剂，用于成像前列腺癌患者的 PSMA 阳性病变。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 Lantheus</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>为什么黄金如此钟爱特朗普，就像特朗普钟爱黄金一样</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>谷歌的 Gemini 3 让博通飙升：TPU 成为焦点</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>Palantir 不仅仅是在乘坐 AI 热潮——它正在指挥这一切</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE5USA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE5USA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Lantheus 吗？</h2>
<p>在你考虑 Lantheus 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Lantheus 并不在名单上。</p>
<p>虽然 Lantheus 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Lantheus控股

<p>CreativeOne Wealth LLC 在第二季度将其在 Lantheus Holdings, Inc. 的股份增加了 26.8%。分析师对 Lantheus 的评级不一，目标价格范围在 70 美元到 84 美元之间。该股票目前交易价格为 58.75 美元，市场共识目标价格为 74.17 美元。Lantheus 专注于心脏、癌症及其他疾病的诊断和治疗产品</p>

<p>CreativeOne Wealth LLC raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 26.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,396 shares of the medical equipment provider's stock after acquiring an additional 4,316 shares during the quarter. CreativeOne Wealth LLC's holdings in Lantheus were worth $1,670,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>CreativeOne Wealth LLC 在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Lantheus Holdings, Inc.（NASDAQ:LNTH - 免费报告）中的股份增加了 26.8%。该机构投资者在本季度额外购买了 4,316 股后，持有 20,396 股该医疗设备提供商的股票。CreativeOne Wealth LLC 在 Lantheus 的持股在最近的报告期末价值为 1,670,000 美元。</p>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>制药火售：3 只 RSI 显示你不应忽视的股票</li>
</ul>
</div><p>Other large investors have also recently made changes to their positions in the company. Nuveen LLC bought a new stake in Lantheus during the first quarter valued at about $55,941,000. Epoch Investment Partners Inc. purchased a new stake in shares of Lantheus during the first quarter valued at about $35,548,000. Mackenzie Financial Corp boosted its holdings in shares of Lantheus by 129.2% in the 1st quarter. Mackenzie Financial Corp now owns 497,437 shares of the medical equipment provider's stock valued at $48,550,000 after buying an additional 280,381 shares in the last quarter. Nitorum Capital L.P. bought a new stake in shares of Lantheus in the 1st quarter valued at about $23,261,000. Finally, Reinhart Partners LLC. grew its position in shares of Lantheus by 16.4% in the 2nd quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider's stock worth $114,905,000 after buying an additional 197,719 shares during the last quarter. 99.06% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者最近也对该公司的持仓进行了调整。Nuveen LLC 在第一季度购买了价值约 55,941,000 美元的 Lantheus 新股份。Epoch Investment Partners Inc.在第一季度购买了价值约 35,548,000 美元的 Lantheus 新股份。Mackenzie Financial Corp 在第一季度将其在 Lantheus 的持股增加了 129.2%。Mackenzie Financial Corp 现在拥有 497,437 股该医疗设备提供商的股票，价值为 48,550,000 美元，此前在上个季度又购买了 280,381 股。Nitorum Capital L.P.在第一季度购买了价值约 23,261,000 美元的 Lantheus 新股份。最后，Reinhart Partners LLC 在第二季度将其在 Lantheus 的持仓增加了 16.4%。Reinhart Partners LLC 现在拥有 1,403,659 股该医疗设备提供商的股票，价值为 114,905,000 美元，此前在上个季度又购买了 197,719 股。99.06% 的股票由机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of equities research analysts recently commented on LNTH shares. B. Riley decreased their target price on shares of Lantheus from $109.00 to $84.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, September 16th. Truist Financial reiterated a &#34;hold&#34; rating and set a $61.00 price objective (down previously from $63.00) on shares of Lantheus in a report on Monday, November 10th. Mizuho dropped their target price on Lantheus from $120.00 to $70.00 and set an &#34;outperform&#34; rating on the stock in a research note on Thursday, August 7th. JMP Securities reduced their target price on Lantheus from $112.00 to $73.00 and set a &#34;market outperform&#34; rating on the stock in a research report on Thursday, August 7th. Finally, Weiss Ratings cut Lantheus from a &#34;hold (c-)&#34; rating to a &#34;sell (d+)&#34; rating in a research note on Saturday, October 25th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of &#34;Hold&#34; and a consensus target price of $74.17.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 LNTH 股票发表了评论。B. Riley 在 2023 年 9 月 16 日的研究报告中将 Lantheus 的目标价格从 109.00 美元下调至 84.00 美元，并对该公司给予了 “买入” 评级。Truist Financial 在 2023 年 11 月 10 日的报告中重申了 “持有” 评级，并将 Lantheus 的目标价格设定为 61.00 美元（之前为 63.00 美元）。Mizuho 在 2023 年 8 月 7 日的研究报告中将 Lantheus 的目标价格从 120.00 美元下调至 70.00 美元，并对该股票给予了 “跑赢大盘” 评级。JMP Securities 在 2023 年 8 月 7 日的研究报告中将 Lantheus 的目标价格从 112.00 美元下调至 73.00 美元，并对该股票给予了 “市场跑赢” 评级。最后，Weiss Ratings 在 2023 年 10 月 25 日的研究报告中将 Lantheus 的评级从 “持有（c-）” 下调至 “卖出（d+）”。四位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，共识目标价格为 74.17 美元。</p>
</div><ul>
<li>Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>大规模突破：该 ETF 信号显示小型股将大幅上涨</li>
</ul>
</div><p><strong>View Our Latest Report on LNTH</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 LNTH 的最新报告</strong></p>
</div><h2>Lantheus Trading Down 0.5%</h2>
<div class="lb-trans"><h2>Lantheus 股价下跌 0.5%</h2>
</div><p>Lantheus stock opened at $58.75 on Thursday. The stock has a 50-day moving average price of $54.28 and a 200 day moving average price of $64.44. The company has a market capitalization of $3.90 billion, a price-to-earnings ratio of 15.63 and a beta of 0.04. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49.</p>
<div class="lb-trans"><p>Lantheus 股票在周四开盘价为 58.75 美元。该股票的 50 日移动平均价格为 54.28 美元，200 日移动平均价格为 64.44 美元。该公司的市值为 39 亿美元，市盈率为 15.63，贝塔值为 0.04。Lantheus Holdings, Inc.的 52 周低点为 47.25 美元，52 周高点为 111.29 美元。该公司的速动比率为 4.07，流动比率为 4.29，债务股本比率为 0.49。</p>
</div><ul>
<li>Are These Medical Device Makers Getting Ready To Rally?</li>
</ul>
<div class="lb-trans"><ul>
<li>这些医疗设备制造商准备反弹吗？</li>
</ul>
</div><p>Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $92.51 million during the quarter. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.</p>
<div class="lb-trans"><p>Lantheus（NASDAQ:LNTH - 获取免费报告）最后一次公布季度财报是在 2023 年 5 月 17 日。该医疗设备提供商报告本季度每股收益为 0.05 美元。Lantheus 的净利润率为 17.82%，股本回报率为 34.06%。该业务在本季度的收入为 9251 万美元。卖方分析师预计 Lantheus Holdings, Inc.在本年度将发布 6.01 美元的每股收益。</p>
</div><h2>Lantheus Profile</h2>
<div class="lb-trans"><h2>Lantheus 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.</p>
<div class="lb-trans"><p>Lantheus Holdings, Inc.开发、制造和商业化诊断和治疗产品，帮助临床医生在全球范围内诊断和治疗心脏病、癌症及其他疾病。它提供 DEFINITY，一种用于超声心动图检查的可注射超声增强剂；TechneLite，一种用于核医学程序的锝生成器；氙-133，一种用于评估肺功能的放射性药物气体；Neurolite，一种可注射成像剂，用于识别因中风导致的脑部血流被阻断或减少的区域；Cardiolite，一种可注射的 Tc-99m 标记成像剂，用于评估心肌的血流；以及 PYLARIFY，一种 F 18 标记的 PSMA 靶向 PET 成像剂，用于成像前列腺癌患者的 PSMA 阳性病变。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Lantheus</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Why Gold Loves Trump as Much as Trump Loves Gold</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>Google's Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage</li>
<li>Canadian Penny Stocks: Can They Make You Rich?</li>
<li>Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Lantheus</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>为什么黄金如此钟爱特朗普，就像特朗普钟爱黄金一样</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>谷歌的 Gemini 3 让博通飙升：TPU 成为焦点</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>Palantir 不仅仅是在乘坐 AI 热潮——它正在指挥这一切</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE5USA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=LNTH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lantheus Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Lantheus 吗？</h2>
</div><p>Before you consider Lantheus, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Lantheus 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Lantheus 并不在名单上。</p>
</div><p>While Lantheus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lantheus 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CreativeOne Wealth LLC 增持了 Lantheus 控股公司的股份 $LNTH